Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment

Genes and Nutrition

Volumn 7, Issue 1, 2012, Pages 63-74

  Sylvester, Paul W ^a  

^a UNIVERSITY OF LOUISIANA AT MONROE   (United States)

Author keywords

Tocotrienol; Breast cancer; Erlotinib; Gefitinib; Statins; Vitamin E

Indexed keywords

ATORVASTATIN; CERIVASTATIN; COMPACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUINDOSTATIN; GAMMA TOCOTRIENOL; GEFITINIB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; PROTEIN TYROSINE KINASE INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL VIABILITY; COLORECTAL CANCER; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG MEGADOSE; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; LUNG CANCER; METASTASIS; MYOPATHY; NONHUMAN; OVARY CANCER; PROSTATE CANCER; SIGNAL TRANSDUCTION;

EID: 84860772715     PISSN: 15558932     EISSN: 18653499     Source Type: Journal    
DOI: 10.1007/s12263-011-0225-y     Document Type: Conference Paper

References (80)

1. American Cancer Society (2009) Cancer facts and figures. American Cancer Society Inc., Atlanta, GA
2. Arber N, Doki Y, Han EK, Sgambato A, Zhou P, Kim NH, Delohery T, Klein MG, Holt PR, Weinstein IB (1997) Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells. Cancer Res 57:1569-1574 (Pubitemid 27175576)
3. Arnold A, Papanikolaou A (2005) Cyclin D1 in breast cancer pathogenesis. J Clin Oncol 23:4215-4224 (Pubitemid 46211327)
4. Bachawal SV, Wali VB, Sylvester PW (2010a) Combined gammatocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells. Anticancer Res 30:429-437
5. Bachawal SV, Wali VB, Sylvester PW (2010b) Enhanced antiproliferative and apoptotic response to combined treatment of gammatocotrienol with erlotinib or gefitinib in mammary tumor cells. BMC Cancer 10:84
6. Bartkova J, Lukas J, Muller H, Lutzhoft D, Strauss M, Bartek J (1994) Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353-361 (Pubitemid 24168609)
7. Baserga R, Wiebel F (1969) The cell cycle of mammalian cells. Int Rev Exp Pathol 7:1-30
8. Bowman T, Garcia R, Turkson J, Jove R (2000) STATs in oncogenesis. Oncogene 19:2474-2488 (Pubitemid 30339203)
9. Britten CD (2004) Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 3:1335-1342 (Pubitemid 39440177)
10. Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A (1978) Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML- 236B), a competitive inhibitor of the reductase. J Biol Chem 253:1121-1128 (Pubitemid 8288831)
11. Caldon CE, Daly RJ, Sutherland RL, Musgrove EA (2006) Cell cycle control in breast cancer cells. J Cell Biochem 97:261-274 (Pubitemid 43167144)
12. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC (2006) Breast cancer growth prevention by statins. Cancer Res 66:8707-8714 (Pubitemid 44449187)
13. Carraway KL 3rd, Cantley LC (1994) A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell 78:5-8
14. Chan KK, Oza AM, Siu LL (2003) The statins as anticancer agents. Clin Cancer Res 9:10-19 (Pubitemid 36109711)
15. Coleman ML, Marshall CJ, Olson MF (2004) RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol 5:355-366 (Pubitemid 38579473)
16. Cottrell RC (1991) Introduction: nutritional aspects of palm oil. Am J Clin Nutr 53:989S-1009S
17. Downward J (1998) Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 10:262-267 (Pubitemid 28174769)
18. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20:2499-2513 (Pubitemid 32531347)
19. Gerson RJ, MacDonald JS, Alberts AW, Kornbrust DJ, Majka JA, Stubbs RJ, Bokelman DL (1989) Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 87:28S-38S
20. Goh SH, Hew NF, Norhanom AW, Yadav M (1994) Inhibition of tumour promotion by various palm-oil tocotrienols. Int J Cancer 57:529-531 (Pubitemid 24173098)
21. Goldstein JL, Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430
22. Goldstein JL, DeBose-Boyd RA, Brown MS (2006) Protein sensors for membrane sterols. Cell 124:35-46
23. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ (2004) Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 30:609-641 (Pubitemid 39451828)
24. Grillo M, Bott MJ, Khandke N, McGinnis JP, Miranda M, Meyyappan M, Rosfjord EC, Rabindran SK (2006) Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression. Breast Cancer Res Treat 95:185-194
25. Hall M, Peters G (1996) Genetic alterations of cyclins, cyclindependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68:67-108 (Pubitemid 26099813)
26. Hermes M, Schormann W, Brulport M, Uhlemann K, Lupatsch F, Horn LC, Schumann A, Allgaier C, Weishaupt M, Engeland K, Muller GA, Mossner J, Bauer A, Schiffer IB, Gebhard S, Schmidt M, Lausch E, Prawitt D, Wilhelm C, Hengstler JG (2008) Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model. Br J Cancer 98:1525-1532 (Pubitemid 351652324)
27. Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y (1996) ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15:254-264 (Pubitemid 26029205)
28. Knowlden JM, Gee JM, Seery LT, Farrow L, Gullick WJ, Ellis IO, Blamey RW, Robertson JF, Nicholson RI (1998) c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene 17:1949-1957 (Pubitemid 28488463)
29. Kornbrust DJ, MacDonald JS, Peter CP, Duchai DM, Stubbs RJ, Germershausen JI, Alberts AW (1989) Toxicity of the HMGcoenzyme A reductase inhibitor, lovastatin, to rabbits. J Pharmacol Exp Ther 248:498-505 (Pubitemid 19090215)
30. Liang J, Slingerland JM (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2:339-345
31. Ling YH, Lin R, Perez-Soler R (2008) Erlotinib induces mitochondrial- mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylationdependent activation of BAX and BAK. Mol Pharmacol 74:793-806
32. Maltese WA, Defendini R, Green RA, Sheridan KM, Donley DK (1985) Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl- coenzyme A reductase. J Clin Invest 76:1748-1754 (Pubitemid 16196041)
33. Mantha AJ, Hanson JE, Goss G, Lagarde AE, Lorimer IA, Dimitroulakos J (2005) Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor. Clin Cancer Res 11:2398-2407 (Pubitemid 40490201)
34. Marshall E (1993) Epidemiology. Search for a killer: focus shifts from fat to hormones [news] [see comments]. Science 259:618-621
35. Massague J (2004) G1 cell-cycle control and cancer. Nature 432:298-306 (Pubitemid 39551657)
36. Massague J, Pandiella A (1993) Membrane-anchored growth factors. Annu Rev Biochem 62:515-541 (Pubitemid 23237880)
37. Matsushime H, Quelle DE, Shurtleff SA, Shibuya M, Sherr CJ, Kato JY (1994) D-type cyclin-dependent kinase activity in mammalian cells. Mol Cell Biol 14:2066-2076 (Pubitemid 24074604)
38. McIntyre BS, Briski KP, Gapor A, Sylvester PW (2000a) Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. Proc Soc Exp Biol Med 224:292-301 (Pubitemid 30643508)
39. McIntyre BS, Briski KP, Tirmenstein MA, Fariss MW, Gapor A, Sylvester PW (2000b) Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. Lipids 35:171-180 (Pubitemid 30183648)
40. Medina D (1974) Mammary tumorigenesis in chemical carcinogentreated mice. II. Dependence on hormone stimulation for tumorigenesis. J Natl Cancer Inst 53:223-226
41. Mo H, Elson CE (2004) Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229:567-585 (Pubitemid 38878903)
42. Nagasawa H, Yanai R, Taniguchi H (1976) Importance of mammary gland DNA synthesis on carcinogen-induced mammary tumorigenesis in rats. Cancer Res 36:2223-2226
43. Nakanishi M, Goldstein JL, Brown MS (1988) Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Mevalonatederived product inhibits translation of mRNA and accelerates degradation of enzyme. J Biol Chem 263:8929-8937
44. Nakayama M, Ju HR, Sugano M, Hirose N, Ueki T, Doi F, Eynard AR (1993) Effect of dietary fat and cholesterol on dimethylbenz[a]-anthracene-induced mammary tumorigenesis in Sprague- Dawley rats. Anticancer Res 13:691-698 (Pubitemid 23216968)
45. Nandi S, Guzman RC, Yang J (1995) Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92:3650-3657
46. Norbury C, Nurse P (1992) Animal cell cycles and their control. Annu Rev Biochem 61:441-470
47. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S (2002) Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13:65-72 (Pubitemid 34436727)
48. Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS (2003) Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocr Relat Cancer 10:1-21 (Pubitemid 36457237)
49. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H (2004) Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182, 780) in breast cancer cells. Br J Cancer 90:236-244 (Pubitemid 38174967)
50. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE (1999) ErbB receptor-induced activation of stat transcription factors is mediated by Src tyrosine kinases. J Biol Chem 274:17209-17218
51. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19:3159-3167 (Pubitemid 30428195)
52. Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ (1993) Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl- coenzyme A reductase. J Biol Chem 268:11230-11238 (Pubitemid 23162316)
53. Rogers AE, Lee SY (1986) Chemically-induced mammary gland tumors in rats: modulation by dietary fat. Prog Clin Biol Res 222:255-282
54. Russo IH, Russo J (1978) Developmental stage of the rat mammary gland as determinant of its susceptibility to 7, 12-dimethylbenz[a]anthracene. J Natl Cancer Inst 61:1439-1449 (Pubitemid 9070679)
55. Samant GV, Sylvester PW (2006) gamma-Tocotrienol inhibits ErbB3-dependent PI3K/Akt mitogenic signalling in neoplastic mammary epithelial cells. Cell Prolif 39:563-574 (Pubitemid 44760206)
56. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225
57. Sears RC, Nevins JR (2002) Signaling networks that link cell proliferation and cell fate. J Biol Chem 277:11617-11620 (Pubitemid 34952710)
58. Seeger H, Wallwiener D, Mueck AO (2003) Statins can inhibit proliferation of human breast cancer cells in vitro. Exp Clin Endocrinol Diabetes 111:47-48 (Pubitemid 36336817)
59. Shah SJ, Sylvester PW (2005) Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. Exp Biol Med 230:235-241 (Pubitemid 40478247)
60. Shapiro GI (2006) Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783 (Pubitemid 46628473)
61. Sherr CJ (1993) Mammalian G1 cyclins. Cell 73:1059-1065
62. Shibata MA, Kavanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE (2003) Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 24:453-459 (Pubitemid 36432640)
63. Shibata MA, Ito Y, Morimoto J, Otsuki Y (2004) Lovastatin inhibits tumor growth and lung metastasis in mouse mammary carcinoma model: a p53-independent mitochondrial-mediated apoptotic mechanism. Carcinogenesis 25:1887-1898 (Pubitemid 39405908)
64. Shirode AB, Sylvester PW (2010) Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling. Biomed Pharmacother 64:327-332
65. Sundram K, Khor HT, Ong AS (1990) Effect of dietary palm oil and its fractions on rat plasma and high density lipoprotein lipids. Lipids 25:187-193 (Pubitemid 20135049)
66. Sylvester PW, Shah SJ (2005) Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. Front Biosci 10:699-709
67. Sylvester PW, Theriault A (2003) Role of tocotrienols in the prevention of cardiovascular disease and breast cancer. Curr Top Nutraceutical Res 1:121-136
68. Sylvester PW, Aylsworth CF, Van Vugt DA, Meites J (1983) Effects of alterations in early hormonal environment on development and hormone dependency of carcinogen-induced mammary tumors in rats. Cancer Res 43:5342-5346 (Pubitemid 14230149)
69. Sylvester PW, Ip C, Ip MM (1986a) Effects of high dietary fat on the growth and development of ovarian-independent carcinogeninduced mammary tumors in rats. Cancer Res 46:763-769 (Pubitemid 16145435)
70. Sylvester PW, Russell M, Ip MM, Ip C (1986b) Comparative effects of different animal and vegetable fats fed before and during carcinogen administration on mammary tumorigenesis, sexual maturation, and endocrine function in rats. Cancer Res 46:757-762 (Pubitemid 16145434)
71. Thibault A, Samid D, Tompkins AC, Figg WD, Cooper MR, Hohl RJ, Trepel J, Liang B, Patronas N, Venzon DJ, Reed E, Myers CE (1996) Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2:483-491
72. Toker A (2000) Protein kinases as mediators of phosphoinositide 3-kinase signaling. Mol Pharmacol 57:652-658 (Pubitemid 30183703)
73. Torii S, Yamamoto T, Tsuchiya Y, Nishida E (2006) ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci 97:697-702 (Pubitemid 43983780)
74. Tran H, Brunet A, Griffith EC, Greenberg ME (2003) The many forks in FOXO's road. Sci STKE 2003:RE5
75. Tzahar E, Pinkas-Kramarski R, Moyer JD, Klapper LN, Alroy I, Levkowitz G, Shelly M, Henis S, Eisenstein M, Ratzkin BJ, Sela M, Andrews GC, Yarden Y (1997) Bivalence of EGF-like ligands drives the ErbB signaling network. EMBO J 16:4938-4950 (Pubitemid 27348403)
76. Vogel VG (1993) Breast cancer risk: weaving facts into fabric. Breast Cancer Res Treat 28:91-96 (Pubitemid 24056080)
77. Wali VB, Sylvester PW (2007) Synergistic antiproliferative effects of gamma-tocotrienol and statin treatment on mammary tumor cells. Lipids 42:1113-1123 (Pubitemid 350303593)
78. Wali VB, Bachawal SV, Sylvester PW (2009a) Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment. Lipids 44:925-934
79. Wali VB, Bachawal SV, Sylvester PW (2009b) Combined treatment of gamma-tocotrienol with statins induce mammary tumor cell cycle arrest in G1. Exp Biol Med (Maywood) 234:639-650
80. Yarden Y (2001) Biology of HER2 and its importance in breast cancer. Oncology 61(Suppl 2):1-13 (Pubitemid 33033419)